MD Anderson's Path-IO machine learning platform accurately predicts immunotherapy responses in metastatic non-small cell lung cancer, surpassing current biomarker standards.
Key Details
- 1Path-IO uses routine pathological slides to identify features predicting immunotherapy response in NSCLC patients.
- 2In validation on over 1,000 patients across multiple institutions and countries, Path-IO significantly outperformed PD-L1 testing, the current standard biomarker.
- 3The AI model stratified patients into high- and low-risk groups, with high-risk patients experiencing double the probability of death or progression.
- 4Unlike 'black box' models, Path-IO leverages established tissue features for explainable, clinically translatable decision-making.
- 5Researchers are integrating radiomics and clinical data to further improve Path-IO's prediction accuracy and plan to include CT, genomics, and other multimodal data in the future.
- 6Prospective clinical validation is the next planned step, and the model may evolve into a digital twin framework for comprehensive clinical decision support.
Why It Matters
Path-IO's superior accuracy and explainability provide a pathway for more personalized and effective treatment decisions in oncology. The integration with radiomics and clinical imaging data signals a promising future for multimodal AI in precision medicine, especially for radiology and pathology collaborations.
Source
EurekAlert
Related News
•EurekAlert
AI Pathology Tool SÉMIL Improves Stage II Bowel Cancer Risk Assessment
A La Trobe University-developed AI tool accurately predicts relapse risk in stage II bowel cancer using digital pathology images and descriptions.
•EurekAlert
AI Tool Predicts Which Rectal Cancer Patients Benefit from Intensive Therapy
UCL researchers developed an AI that analyzes biopsy slides to identify rectal cancer patients who benefit from adding irinotecan to standard chemoradiotherapy.
•EurekAlert
AI-Guided Handheld Cardiac Ultrasound Reduces Referrals and Costs in Spain
AI-guided handheld cardiac ultrasound enables primary care physicians to detect heart failure, reducing specialist referrals and saving costs.